Ticker brief

ONCY

last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
9
authors 14d
5
crowd 14d
-0.6σ

No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.

Sentiment — last 14 days
daily mean sentiment, 2026-10-12 → 2026-10-14 · now +0.37 (−1 bearish … +1 bullish)
Who spoke5
authorgradetrader scoresignalsmean sent
@PrismMarketViewC·3+0.22
@PrismDMA-2.763+0.27
@faststocknewssC+1.701+0.35
@Analytica_XB-0.291-0.10
@BiopharmIQB·1+0.40
Recent signals9of 9 in 14d — receipts included
date (PT)authorsentwhat they saidsince thenreceipt
2026-10-14@BiopharmIQ+0.40Lists opening price moves tied to company catalysts; output is capped at the first six tickers.·
2026-10-14@PrismDM+0.30The tweet reports intraday percentage and price moves for four identifiable stocks.·
2026-10-14@PrismMarketView+0.40Midday mover list reports large gains and losses.·
2026-10-13@PrismDM+0.25Oncolytics secured method-of-use patents in several countries, with a U.S. patent expected.·
2026-10-13@PrismMarketView+0.20Reports new international method-of-use patent protection and pending U.S. review plans.·
2026-10-13@Analytica_X-0.10Quantified watchlist combines catalysts, insider transactions, dates and financing risks.·
2026-10-12@faststocknewss+0.35Reports new pelareorep patent issuance, further applications and expected US protection extending into the late 2040s.·
2026-10-12@PrismDM+0.25Surveys five clinical-stage metastatic breast-cancer programs while emphasizing early data and binary risks.·
2026-10-12@PrismMarketView+0.05Presents a basket of metastatic-breast-cancer biotechs and their clinical programs while stressing binary risks.·

“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.